Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Hum Mutat. 2020 Jun 12;41(9):1555–1562. doi: 10.1002/humu.24060

Table 5.

Proposed point system for the incorporation of breast tumor pathology into the existing ACMG/AMP PP4 criterion for TP53*

Proband breast tumor phenotype Points assigned Final code strength
HER2+ diagnosed <40 0.5   Sum points across all probands:
• Total 1-1.5 Points: PP4
• Total 2+ Points: PP4_Moderate
*

Proband does not otherwise meet existing clinical criteria for LFS (Classic LFS or Chompret 2015) due to breast cancer diagnosis <31y. HER2 status for first breast tumor diagnosis only.